Hey Sanofi, you need to freshen up your pipeline, perhaps with M&A: report

More than 75% of Sanofi's sales come from products over 10 years old—a quandary that can't be solved unless the French pharma giant embraces M&A to boost its pipeline, said analysts at Vantage. Which company offers the best model for using deals to freshen up the pipeline? That would be Gilead, they said.